

TEKLA LIFE SCIENCES INVESTORS  
Form N-PX  
August 30, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

OMB APPROVAL  
OMB Number: 3235-0582  
Expires: March 31, 2018  
Estimated average burden  
hours per response.....7.2

Washington, D.C. 20549

**FORM N-PX**

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

**Tekla Life Sciences Investors**

(Exact name of registrant as specified in charter)

**100 Federal Street, 19th Floor, Boston, MA**  
(Address of principal executive offices)

**02110**  
(Zip code)

**Laura Woodward**

**Tekla Life Sciences Investors**

**100 Federal Street, 19th Floor, Boston MA 02110**

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

## Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/16-6/30/17**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

---

**Item 1. Proxy Voting Record.**

---

*Vote Summary***ACCELERATE DIAGNOSTICS**

<b>Security</b>	00430H102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AXDX	<b>Meeting Date</b>	04-May-2017
<b>Record Date</b>	15-Mar-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DIRECTOR	Management		
	1	LAWRENCE MEHREN	For	For
	2	MARK MILLER	For	For
	3	JOHN PATIENCE	For	For
	4	JACK SCHULER	For	For
	5	MATTHEW STROBECK, PH.D.	For	For
	6	FRANK J.M. TEN BRINK	For	For
	7	TOM BROWN	For	For
2.	TO APPROVE THE THIRD AMENDMENT TO THE COMPANY S 2012 OMNIBUS EQUITY INCENTIVE PLAN AND REAPPROVE THE MATERIAL TERMS OF THE PLAN FOR PURPOSES OF SECTION 162(M) OF THE INTERNAL REVENUE CODE OF 1986.	Management	For	For
3.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT PUBLIC ACCOUNTANTS OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**ACCELERON PHARMA INC.**

<b>Security</b>	00434H108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XLRN	<b>Meeting Date</b>	01-Jun-2017
<b>Record Date</b>	04-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DIRECTOR	Management		
	1	JEAN M. GEORGE	For	For
	2	GEORGE GOLUMBESKI, PH.D	For	For
	3	THOMAS A. MCCOURT	For	For
	4	FRANCOIS NADER, M.D.	For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
3.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING	Management	For	For

DECEMBER 31, 2017.

## ADAPT IMMUNE THERAPEUTICS PLC

<b>Security</b>	00653A107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ADAP	<b>Meeting Date</b>	21-Jun-2017
<b>Record Date</b>	04-May-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	TO RE-ELECT AS A DIRECTOR, BARBARA DUNCAN, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
2.	TO RE-ELECT AS A DIRECTOR, GILES KERR, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
3.	TO RE-ELECT AS A DIRECTOR, TAL ZAKS, WHO RETIRES IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
4.	TO RE-ELECT AS A DIRECTOR, ALI BEHBAHANI, WHO RETIRES BY ROTATION IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
5.	TO RE-ELECT AS A DIRECTOR, PETER THOMPSON, WHO RETIRES BY ROTATION IN ACCORDANCE WITH THE ARTICLES OF ASSOCIATION.	Management	For	For
6.	TO RE-APPOINT KPMG LLP AS OUR U.K. STATUTORY AUDITORS UNDER THE ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
7.	TO AUTHORIZE THE AUDIT COMMITTEE TO DETERMINE OUR U.K. ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
8.	TO RECEIVE THE U.K. STATUTORY ANNUAL ACCOUNTS AND REPORTS FOR ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For
9.	TO RECEIVE AND APPROVE OUR U.K. STATUTORY DIRECTORS REMUNERATION REPORT FOR THE YEAR ENDED DECEMBER 31, 2016.	Management	For	For
10.	TO AUTHORISE THE DIRECTORS UNDER SECTION 551 OF THE U.K. COMPANIES ACT 2006 (THE 2006 ACT ) TO ALLOT ORDINARY SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR TO CONVERT ANY SECURITY INTO ORDINARY SHARES.	Management	For	For
11.	TO AUTHORISE THE DIRECTORS TO ALLOT ORDINARY SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR CONVERT ANY SECURITY INTO ORDINARY ...(DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL).	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AKORN, INC.

<b>Security</b>	009728106	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	AKRX	<b>Meeting Date</b>	16-Dec-2016
<b>Record Date</b>	28-Oct-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	PROPOSAL TO APPROVE THE AKORN, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
2.	PROPOSAL TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE AKORN, INC. 2014 STOCK OPTION PLAN.	Management	For	For

AKORN, INC.

<b>Security</b>	009728106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AKRX	<b>Meeting Date</b>	27-Apr-2017
<b>Record Date</b>	13-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 JOHN KAPOOR, PHD		For	For
	2 KENNETH ABRAMOWITZ		For	For
	3 ADRIENNE GRAVES, PHD		For	For
	4 RONALD JOHNSON		For	For
	5 STEVEN MEYER		For	For
	6 TERRY ALLISON RAPPUHN		For	For
	7 BRIAN TAMBI		For	For
	8 ALAN WEINSTEIN		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF BDO USA, LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	PROPOSAL TO APPROVE THE 2017 OMNIBUS INCENTIVE COMPENSATION PLAN.	Management	For	For
4.	PROPOSAL TO APPROVE, THROUGH A NON- BINDING ADVISORY VOTE, THE FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON THE COMPANY S EXECUTIVE COMPENSATION PROGRAMS.	Management	1 Year	For
5.	PROPOSAL TO APPROVE, THROUGH A NON- BINDING ADVISORY VOTE, THE COMPANY S EXECUTIVE COMPENSATION PROGRAM AS DESCRIBED IN THE COMPANY S 2017 PROXY STATEMENT.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AKORN, INC.

<b>Security</b>	009728106	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	AKRX	<b>Meeting Date</b>	19-Jul-2017
<b>Record Date</b>	09-Jun-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	TO APPROVE THE AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 24, 2017, BY AND AMONG FRESENIUS KABI AG, QUERCUS ACQUISITION, INC., AKORN, INC. AND, SOLELY FOR PURPOSES OF ARTICLE VIII THEREIN, FRESENIUS SE & CO. KGAA.	Management	For	For
2.	TO APPROVE, BY NON-BINDING, ADVISORY VOTE, THE COMPENSATION THAT MAY BE PAID OR MAY BECOME PAYABLE TO AKORN, INC. S NAMED EXECUTIVE OFFICERS IN CONNECTION WITH, OR FOLLOWING, THE CONSUMMATION OF THE MERGER CONTEMPLATED BY THE AGREEMENT AND PLAN OF MERGER.	Management	For	For
3.	TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR TIME, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IN THE EVENT THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE SPECIAL MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF TO ADOPT THE AGREEMENT AND PLAN OF MERGER.	Management	For	For

ALEXION PHARMACEUTICALS, INC.

<b>Security</b>	015351109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALXN	<b>Meeting Date</b>	10-May-2017
<b>Record Date</b>	14-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: FELIX J. BAKER	Management	For	For
1B.	ELECTION OF DIRECTOR: DAVID R. BRENNAN	Management	For	For
1C.	ELECTION OF DIRECTOR: M. MICHELE BURNS	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN	Management	For	For
1E.	ELECTION OF DIRECTOR: LUDWIG N. HANTSON	Management	For	For
1F.	ELECTION OF DIRECTOR: JOHN T. MOLLEN	Management	For	For
1G.	ELECTION OF DIRECTOR: R. DOUGLAS NORBY	Management	For	For
1H.	ELECTION OF DIRECTOR: ALVIN S. PARVEN	Management	For	For
1I.	ELECTION OF DIRECTOR: ANDREAS RUMMELT	Management	For	For
1J.	ELECTION OF DIRECTOR: ANN M. VENEMAN	Management	For	For
2.	TO APPROVE ALEXION S 2017 INCENTIVE PLAN.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3.	RATIFICATION OF APPOINTMENT BY THE BOARD OF DIRECTORS OF PRICEWATERHOUSECOOPERS LLP AS ALEXION S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.	Management	For	For
4.	APPROVAL OF A NON-BINDING ADVISORY VOTE OF THE 2016 COMPENSATION PAID TO ALEXION S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
6.	TO REQUEST THE BOARD IMPLEMENT CONFIDENTIAL SHAREHOLDER VOTING ON EXECUTIVE PAY MATTERS.	Shareholder	Against	For

---



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**ALLERGAN PLC**

<b>Security Ticker Symbol Record Date</b>	G0177J108 AGN 08-Mar-2017	<b>Meeting Type Meeting Date</b>	Annual 04-May-2017
---	---------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: NESLI BASGOZ, M.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: PAUL M. BISARO	Management	For	For
1C.	ELECTION OF DIRECTOR: JAMES H. BLOEM	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHER W. BODINE	Management	For	For
1E.	ELECTION OF DIRECTOR: ADRIANE M. BROWN	Management	For	For
1F.	ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN	Management	For	For
1G.	ELECTION OF DIRECTOR: CATHERINE M. KLEMA	Management	For	For
1H.	ELECTION OF DIRECTOR: PETER J. MCDONNELL, M.D.	Management	For	For
1I.	ELECTION OF DIRECTOR: PATRICK J. O SULLIVAN	Management	For	For
1J.	ELECTION OF DIRECTOR: BRENTON L. SAUNDERS	Management	For	For
1K.	ELECTION OF DIRECTOR: RONALD R. TAYLOR	Management	For	For
1L.	ELECTION OF DIRECTOR: FRED G. WEISS	Management	For	For
2.	TO APPROVE, IN A NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
3.	TO RECOMMEND, IN A NON-BINDING VOTE, WHETHER A SHAREHOLDER VOTE TO APPROVE THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS SHOULD OCCUR EVERY ONE, TWO OR THREE YEARS.	Management	1 Year	For
4.	TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH ITS AUDIT AND COMPLIANCE COMMITTEE, TO DETERMINE PRICEWATERHOUSECOOPERS LLP S REMUNERATION.	Management	For	For
5.	TO APPROVE THE MATERIAL TERMS OF THE PERFORMANCE GOALS FOR THE PURPOSES OF SECTION 162(M) UNDER THE ALLERGAN PLC 2017 ANNUAL INCENTIVE COMPENSATION PLAN.	Management	For	For
6.	TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN, IF PROPERLY PRESENTED AT THE MEETING.	Shareholder	Against	For

**ALLIQUA BIOMEDICAL, INC.**

<b>Security</b>	019621200	<b>Meeting Type</b>	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Ticker Symbol  
Record Date

ALQA  
28-Apr-2017

Meeting Date

23-Jun-2017

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DAVID JOHNSON		For	For
	2 WINSTON KUNG		For	For
	3 JOSEPH LEONE		For	For
	4 GARY RESTANI		For	For
	5 JEFFREY SKLAR		For	For
	6 MARK WAGNER		For	For
	7 JEROME ZELDIS, MD, PHD.		For	For
2.	APPROVAL TO AUTHORIZE THE BOARD OF DIRECTORS OF THE COMPANY TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY'S STOCKHOLDERS IN 2018, TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY'S COMMON STOCK, AT A RATIO IN THE RANGE OF 1-FOR-3 TO 1-FOR-13.	Management	For	For
3.	APPROVAL OF AN AMENDMENT TO THE COMPANY'S 2014 LONG-TERM INCENTIVE PLAN, TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE 2014 PLAN BY AN ADDITIONAL 4,000,000 SHARES, TO A TOTAL OF 9,500,000 SHARES.	Management	For	For
4.	TO APPROVE THE ISSUANCE OF MORE THAN 19.99% OF THE COMPANY'S OUTSTANDING COMMON STOCK AT A PRICE PER SHARE LESS THAN BOOK OR MARKET VALUE TO INVESTORS WHO PARTICIPATED IN A PRIVATE PLACEMENT WHICH CLOSED ON FEBRUARY 27, 2017 PURSUANT TO THE MFN ADJUSTMENT.	Management	For	For
5.	TO APPROVE THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK TO JEROME ZELDIS, M.D., PH.D., THE CHAIRMAN OF THE COMPANY'S BOARD OF DIRECTORS, PURSUANT TO THE MFN ADJUSTMENT AT A PER SHARE PURCHASE PRICE LESS THAN THE CLOSING BID PRICE OF THE COMMON STOCK ON FEBRUARY 27, 2017.	Management	For	For
6.	TO APPROVE THE ISSUANCE OF SHARES OF THE COMPANY'S COMMON STOCK ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
7.	RATIFICATION OF THE APPOINTMENT OF MARCUM LLP AS OUR ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
8.	AN ADVISORY VOTE ON EXECUTIVE COMPENSATION AS DISCLOSED IN THESE MATERIALS.	Management	For	For

## ALNYLAM PHARMACEUTICALS, INC.

<b>Security</b>	02043Q107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALNY	<b>Meeting Date</b>	02-May-2017
<b>Record Date</b>	10-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: MICHAEL W. BONNEY	Management	For	For
1B.	ELECTION OF DIRECTOR: JOHN M. MARAGANORE, PH.D.	Management	For	For
1C.	ELECTION OF DIRECTOR: PAUL R. SCHIMMEL, PH.D.	Management	For	For
1D.	ELECTION OF DIRECTOR: PHILLIP A. SHARP, PH.D.	Management	For	For
2.	TO APPROVE THE SECOND AMENDED AND RESTATED 2009 STOCK INCENTIVE PLAN.	Management	For	For
3.	TO APPROVE THE AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
4.	TO APPROVE, IN A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF ALNYLAM S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RECOMMEND, IN A NON-BINDING ADVISORY VOTE, THE FREQUENCY OF ADVISORY STOCKHOLDER VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
6.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AS ALNYLAM S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## AMGEN INC.

<b>Security</b>	031162100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMGN	<b>Meeting Date</b>	19-May-2017
<b>Record Date</b>	20-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: DR. DAVID BALTIMORE	Management	For	For
1B.	ELECTION OF DIRECTOR: MR. ROBERT A. BRADWAY	Management	For	For
1C.	ELECTION OF DIRECTOR: MR. FRANCOIS DE CARBONNEL	Management	For	For
1D.	ELECTION OF DIRECTOR: MR. ROBERT A. ECKERT	Management	For	For
1E.	ELECTION OF DIRECTOR: MR. GREG C. GARLAND	Management	For	For
1F.	ELECTION OF DIRECTOR: MR. FRED HASSAN	Management	For	For
1G.	ELECTION OF DIRECTOR: DR. REBECCA M. HENDERSON	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1H.	ELECTION OF DIRECTOR: MR. FRANK C. HERRINGER	Management	For	For
1I.	ELECTION OF DIRECTOR: MR. CHARLES M. HOLLEY, JR.	Management	For	For
1J.	ELECTION OF DIRECTOR: DR. TYLER JACKS	Management	For	For
1K.	ELECTION OF DIRECTOR: MS. ELLEN J. KULLMAN	Management	For	For
1L.	ELECTION OF DIRECTOR: DR. RONALD D. SUGAR	Management	For	For
1M.	ELECTION OF DIRECTOR: DR. R. SANDERS WILLIAMS	Management	For	For
2.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	ADVISORY VOTE TO APPROVE OUR EXECUTIVE COMPENSATION.	Management	For	For
4.	ADVISORY VOTE ON THE FREQUENCY OF FUTURE STOCKHOLDER VOTES TO APPROVE EXECUTIVE COMPENSATION.	Management	1 Year	For
5.	STOCKHOLDER PROPOSAL TO ADOPT MAJORITY VOTES CAST STANDARD FOR MATTERS PRESENTED BY STOCKHOLDERS.	Shareholder	Against	For

---

## AMICUS THERAPEUTICS, INC.

<b>Security</b>	03152W109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOLD	<b>Meeting Date</b>	13-Jun-2017
<b>Record Date</b>	17-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	TED W. LOVE, M.D.	For	For
	2	ROBERT ESSNER	For	For
2.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017	Management	For	For
3.	APPROVE, ON AN ADVISORY BASIS, THE COMPANY S EXECUTIVE COMPENSATION	Management	For	For
4.	APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF THE VOTE ON EXECUTIVE COMPENSATION	Management	1 Year	For

## ARCA BIOPHARMA, INC.

<b>Security</b>	00211Y407	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ABIO	<b>Meeting Date</b>	01-Jun-2017
<b>Record Date</b>	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	DR. MICHAEL R. BRISTOW	For	For
	2	ROBERT E. CONWAY	For	For
2.	TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## ARDELYX, INC

<b>Security</b>	039697107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ARDX	<b>Meeting Date</b>	07-Jun-2017
<b>Record Date</b>	12-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	ROBERT BAZEMORE	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2	GORDON RINGOLD, PH.D.		For	For
3	RICHARD RODGERS		For	For
2.	TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG, LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017.	Management	For	For

---

## AURIS MEDICAL HOLDING AG

<b>Security Ticker Symbol Record Date</b>	H03579101 EARS 10-Mar-2017	<b>Meeting Type Meeting Date</b>	Annual 13-Apr-2017
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF THE ANNUAL REPORT, THE FINANCIAL STATEMENTS AND THE GROUP CONSOLIDATED FINANCIAL STATEMENTS FOR THE 2016 FINANCIAL YEAR	Management	For	For
2.	DISCHARGE OF LIABILITY FOR THE MEMBERS OF THE BOARD OF DIRECTORS AND THE PERSONS ENTRUSTED WITH THE CORPORATION'S MANAGEMENT	Management	For	For
3.	APPROPRIATION OF FINANCIAL RESULTS	Management	For	For
4.1	INCREASE OF THE AUTHORIZED SHARE CAPITAL	Management	For	For
4.2	INCREASE OF THE CONDITIONAL SHARE CAPITAL FOR FINANCING PURPOSES	Management	For	For
4.3	INCREASE OF THE CONDITIONAL SHARE CAPITAL FOR EQUITY INCENTIVE PLANS	Management	Against	Against
5.1	APPROVAL OF THE COMPENSATION OF THE BOARD OF DIRECTORS	Management	For	For
5.2	APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2018 FINANCIAL YEAR	Management	For	For
6.1	RE-ELECTION OF THOMAS MEYER AS MEMBER AND AS CHAIRMAN OF THE BOARD OF DIRECTORS	Management	For	For
6.2	RE-ELECTION OF ARMANDO ANIDO AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.3	RE-ELECTION OF OLIVER KUBLI AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.4	RE-ELECTION OF BERNDT A. MODIG AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.5	RE-ELECTION OF ANTOINE PAPIERNIK-BERKHAEUER AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.6	RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
6.7	ELECTION OF MATS PETER BLOM AS MEMBER OF THE BOARD OF DIRECTORS	Management	For	For
7.1	RE-ELECTION OF ARMANDO ANIDO AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
7.2	RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
8.	RE-ELECTION OF DELOITTE AG AS AUDITORS	Management	For	For
9.	RE-ELECTION OF THE INDEPENDENT PROXY	Management	For	For
10.	GENERAL INSTRUCTION ON NEW PROPOSALS OF THE BOARD OF DIRECTORS	Management	For	For

## AVADEL PHARMACEUTICALS PLC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	05337M104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AVDL	<b>Meeting Date</b>	28-Jun-2017
<b>Record Date</b>	19-May-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF DIRECTOR: CRAIG R. STAPLETON	Management	For	For
1B.	ELECTION OF DIRECTOR: MICHAEL S. ANDERSON	Management	For	For
1C.	ELECTION OF DIRECTOR: FRANCIS J.T. FILDES	Management	For	For
1D.	ELECTION OF DIRECTOR: CHRISTOPHE NAVARRE	Management	For	For
1E.	ELECTION OF DIRECTOR: BENOIT VAN ASSCHE	Management	For	For
1F.	ELECTION OF DIRECTOR: PETER THORNTON	Management	For	For
2.	TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC AUDITOR AND ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE, IN A BINDING VOTE, THE AUDIT COMMITTEE OF THE BOARD TO SET THE INDEPENDENT REGISTERED PUBLIC AUDITOR AND ACCOUNTING FIRM REMUNERATION	Management	For	For
3.	TO APPROVE THE AVADEL PHARMACEUTICALS PLC 2017 OMNIBUS INCENTIVE COMPENSATION PLAN.	Management	For	For
4.	TO APPROVE THE AVADEL PHARMACEUTICALS PLC 2017 EMPLOYEE SHARE PURCHASE PLAN.	Management	For	For

---



**BELLICUM PHARMACEUTICALS INC**

<b>Security</b>	079481107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLCM	<b>Meeting Date</b>	14-Jun-2017
<b>Record Date</b>	17-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 RICHARD A. FAIR		For	For
	2 REID M. HUBER, PH.D.		For	For
	3 JAMES M. DALY		For	For
2.	APPROVAL OF THE COMPANY S 2014 EQUITY INCENTIVE PLAN (THE PLAN ),AS AMENDED, TO, AMONG OTHER THINGS, INCREASE THE SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,100,000 SHARES AND ELIMINATE THE CURRENT PROVISION IN THE PLAN THAT PERMITS THE BOARD TO REPRICE STOCK OPTIONS WITHOUT STOCKHOLDER APPROVAL.	Management	For	For
3.	RATIFICATION OF SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	05-Oct-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DETERMINATION REGARDING SECOND TRANCHE MILESTONE CLOSING OF PREFERRED STOCK FINANCING	Management	For	For
2.	NOTICE OF INTERESTED PARTY TRANSACTIONS	Management	For	For
3.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	02-Mar-2017
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	ELECTION OF DIRECTORS	Management	For	For
2.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

**BIOCLIN THERAPEUTICS, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	02-Mar-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	AMENDMENT AND RESTATEMENT OF RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
2.	SERIES B PREFERRED STOCK FINANCING	Management	For	For
3.	WAIVER OF PREEMPTIVE RIGHTS	Management	For	For
4.	NOTICE OF INTERESTED PARTY TRANSACTIONS	Management	For	For
5.	APPROVAL OF INDEMNIFICATION AGREEMENTS	Management	For	For
6.	AMENDMENT OF 2013 STOCK AND OPTION GRANT PLAN	Management	For	For
7.	GENERAL AUTHORIZING RESOLUTION	Management	For	For

---

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**BIOGEN INC.**

<b>Security</b>	09062X103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BIIB	<b>Meeting Date</b>	07-Jun-2017
<b>Record Date</b>	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: ALEXANDER J. DENNER	Management	For	For
1B.	ELECTION OF DIRECTOR: CAROLINE D. DORSA	Management	For	For
1C.	ELECTION OF DIRECTOR: NANCY L. LEAMING	Management	For	For
1D.	ELECTION OF DIRECTOR: RICHARD C. MULLIGAN	Management	For	For
1E.	ELECTION OF DIRECTOR: ROBERT W. PANGIA	Management	For	For
1F.	ELECTION OF DIRECTOR: STELIOS PAPADOPOULOS	Management	For	For
1G.	ELECTION OF DIRECTOR: BRIAN S. POSNER	Management	For	For
1H.	ELECTION OF DIRECTOR: ERIC K. ROWINSKY	Management	For	For
1I.	ELECTION OF DIRECTOR: LYNN SCHENK	Management	For	For
1J.	ELECTION OF DIRECTOR: STEPHEN A. SHERWIN	Management	For	For
1K.	ELECTION OF DIRECTOR: MICHEL VOUNATSOS	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS BIOGEN INC. S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	SAY ON PAY - TO APPROVE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	For	For
4.	SAY WHEN ON PAY - TO APPROVE AN ADVISORY VOTE ON THE FREQUENCY OF THE ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	1 Year	For
5.	TO APPROVE THE BIOGEN INC. 2017 OMNIBUS EQUITY PLAN.	Management	For	For

**BIOMARIN PHARMACEUTICAL INC.**

<b>Security</b>	09061G101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BMRN	<b>Meeting Date</b>	06-Jun-2017
<b>Record Date</b>	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	JEAN-JACQUES BIENAIME	For	For
	2	WILLARD DERE	For	For
	3	MICHAEL GREY	For	For
	4	ELAINE J. HERON	For	For
	5	V. BRYAN LAWLIS	For	For
	6	ALAN J. LEWIS	For	For
	7	RICHARD A. MEIER	For	For
	8	DAVID PYOTT	For	For
	9	DENNIS J. SLAMON	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2.	TO RATIFY THE SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR BIOMARIN FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF THE STOCKHOLDERS' APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	1 Year	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
5.	TO APPROVE THE 2017 EQUITY INCENTIVE PLAN.	Management	For	For
6.	TO APPROVE AMENDMENTS TO BIOMARIN'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO (I) INCREASE THE TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 250,000,000 SHARES TO 500,000,000 SHARES, AND (II) MAKE CERTAIN MINOR ADMINISTRATIVE CHANGES.	Management	For	For

**BLUEBIRD BIO INC.**

<b>Security</b>	09609G100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLUE	<b>Meeting Date</b>	08-Jun-2017
<b>Record Date</b>	13-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF CLASS I DIRECTOR: NICK LESCHLY	Management	For	For
1B.	ELECTION OF CLASS I DIRECTOR: MARK VACHON	Management	For	For
2.	TO HOLD AN ADVISORY VOTE ON EXECUTIVE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**CARDIOKINETIX INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Jun-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	NOTE FINANCING APPROVAL	Management	For	For
2.	WAIVER OF RIGHT OF FIRST OFFER	Management	For	For
3.	WAIVER OF ANTI-DILUTION ADJUSTMENTS	Management	For	For
4.	GENERAL AUTHROIZING RESOLUTIONS	Management	For	For

**CARDIOKINETIX INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	21-Jun-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	CONSENT TO ASSIGNMENT BY THE STOCKHOLDERS	Management	For	For

**CELGENE CORPORATION**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	151020104	Meeting Type	Annual
Ticker Symbol	CELG	Meeting Date	14-Jun-2017
Record Date	20-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 ROBERT J. HUGIN		For	For
	2 MARK J. ALLES		For	For
	3 RICHARD W BARKER D PHIL		For	For
	4 MICHAEL W. BONNEY		For	For
	5 MICHAEL D. CASEY		For	For
	6 CARRIE S. COX		For	For
	7 MICHAEL A. FRIEDMAN, MD		For	For
	8 JULIA A. HALLER, M.D.		For	For
	9 GILLA S. KAPLAN, PH.D.		For	For
	10 JAMES J. LOUGHLIN		For	For
	11 ERNEST MARIO, PH.D.		For	For
2.	RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE COMPANY S STOCK INCENTIVE PLAN.	Management	For	For
4.	APPROVAL, BY NON-BINDING VOTE, OF EXECUTIVE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF EXECUTIVE COMPENSATION VOTES.	Management	1 Year	For
6.	STOCKHOLDER PROPOSAL TO REQUEST A BY-LAW PROVISION LIMITING MANAGEMENT S ACCESS TO VOTE TALLIES PRIOR TO THE ANNUAL MEETING WITH RESPECT TO CERTAIN EXECUTIVE PAY MATTERS, DESCRIBED IN MORE DETAIL IN THE PROXY STATEMENT.	Shareholder	Against	For

## CELLECTIS S.A.

<b>Security Ticker Symbol Record Date</b>	15117K103 CLLS 12-Jun-2017	<b>Meeting Type Meeting Date</b>	Annual 26-Jun-2017
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2016	Management	For	For
2.	APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2016	Management	For	For
3.	ALLOCATION OF INCOME FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2016	Management	For	For
4.	APPROVAL OF THE AGREEMENTS REFERRED TO IN ARTICLES L. 225-38 AND FOLLOWING OF THE FRENCH COMMERCIAL CODE	Management	For	For
5.	RENEWAL OF THE TERM OF OFFICE OF DIRECTOR OF MR LAURENT ARTHAUD, INDEPENDENT DIRECTOR ACCORDING TO THE RULES OF SEC AND NASDAQ STOCK MARKET	Management	For	For
6.	RENEWAL OF THE TERM OF OFFICE OF DIRECTOR OF MRS ANNICK SCHWEBIG, INDEPENDENT DIRECTOR ACCORDING TO THE RULES OF SEC AND NASDAQ STOCK MARKET	Management	For	For
7.	RENEWAL OF THE TERM OF OFFICE OF DIRECTOR OF MR PIERRE BASTID INDEPENDENT DIRECTOR ACCORDING TO THE RULES OF SEC AND NASDAQ STOCK MARKET	Management	For	For
8.	APPOINTMENT OF A NEW DIRECTOR (MR RAINER BOEHM), INDEPENDENT DIRECTOR ACCORDING TO THE RULES OF SEC AND NASDAQ STOCK MARKET	Management	For	For
9.	APPOINTMENT OF A NEW DIRECTOR (MR HERVE HOPPENOT), INDEPENDENT DIRECTOR ACCORDING TO THE RULES OF SEC AND NASDAQ STOCK MARKET	Management	For	For
10.	APPROVAL OF 2016 STOCK OPTION PLAN AND PAYMENT FOR THE STOCK OPTIONS OR STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON OCTOBER 28, 2016	Management	For	For
11.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO BUY BACK COMPANY SHARES	Management	For	For
12.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF REDUCING THE SHARE CAPITAL THROUGH THE CANCELLATION OF SHARES IN THE CONTEXT OF THE AUTHORIZATION TO BUY BACK ITS OWN SHARES	Management	For	For
13.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL BY ISSUING ORDINARY SHARES AND/OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL AND/OR GIVING	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS MEETING SPECIFIED CHARACTERISTICS			
14.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES OR OF ANY SECURITIES WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS ENSURING THE UNDERWRITING OF THE COMPANY'S EQUITY SECURITIES THAT MAY ARISE AS PART OF AN EQUITY LINE FINANCING	Management	For	For
15.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE BY ISSUING ORDINARY SHARES OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WHILE MAINTAINING THE PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
16.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE THROUGH THE ISSUANCE OF ORDINARY SHARES, SECURITIES GIVING ACCESS TO THE CAPITAL OR ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES AND/OR SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL, WITH WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS THROUGH A PUBLIC OFFERING	Management	For	For
17.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES AND/OR OF ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS OF THE SHAREHOLDERS, THROUGH AN OFFER TO QUALIFIED INVESTORS OR A LIMITED CIRCLE OF INVESTORS WITHIN THE MEANING OF PARAGRAPH II OF ARTICLE L. 411-2 OF THE FRENCH MONETARY AND FINANCIAL CODE	Management	For	For
18.	DELEGATION GRANTED TO THE BOARD OF DIRECTORS TO INCREASE THE NUMBER OF SECURITIES TO BE ISSUED IN CASE OF SHARE CAPITAL INCREASE WITH OR WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
19.	OVERALL LIMITATIONS TO THE AMOUNT OF ISSUANCES MADE UNDER THE THIRTEENTH RESOLUTION, THE FOURTEENTH RESOLUTION, THE FIFTEENTH RESOLUTION, THE SIXTEENTH RESOLUTION, THE SEVENTEENTH RESOLUTION, AND THE EIGHTEENTH RESOLUTION ABOVE	Management	For	For
20.		Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL BY INCORPORATION OF PREMIUMS, RESERVES, PROFITS OR OTHERS

21.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO GRANT OPTIONS TO SUBSCRIBE OR PURCHASE COMPANY S SHARES	Management	For	For
22.	AUTHORIZATION BE GIVEN TO THE BOARD OF DIRECTORS FOR THE ALLOCATION OF FREE SHARES EXISTING AND/OR TO BE ISSUED IN THE FUTURE	Management	For	For
23.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS TO ISSUE WARRANTS GIVING THE RIGHT TO SUBSCRIBE ORDINARY SHARES OF THE COMPANY - CANCELLATION OF THE PREFERENTIAL RIGHT OF SUBSCRIPTION TO THE BENEFIT OF A CATEGORY OF PERSONS MEETING SPECIFIC CHARACTERISTICS	Management	For	For
24.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF ISSUING WARRANTS TO SUBSCRIBE TO AND/OR ACQUIRE REDEEMABLE SHARES (BSAAR) OR SHARE SUBSCRIPTION WARRANTS - WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS IN FAVOR OF THE FOLLOWING CATEGORY OF BENEFICIARIES: EMPLOYEES AND CORPORATE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES	Management	For	For
25.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO FREELY ALLOCATE PREFERRED SHARES OF THE COMPANY TO THE EMPLOYEES AND/OR THE EXECUTIVE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES ENTAILING THE WAIVER BY THE SHAREHOLDERS OF THEIR PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
26.	OVERALL LIMITATIONS TO THE AMOUNT OF ISSUES MADE UNDER THE TWENTY-FIRST RESOLUTION, THE TWENTY-SECOND RESOLUTION, THE TWENTY-THIRD RESOLUTION, THE TWENTY-FOURTH RESOLUTION AND THE TWENTY-FIFTH RESOLUTION ABOVE	Management	For	For
27.	AMENDMENTS TO ARTICLES 4 ( REGISTERED OFFICE ), 15 ( AGREEMENTS SUBJECT TO AUTHORIZATION ) AND 17 ( STATUTORY AUDITORS ) OF THE BYLAWS TO COMPLY WITH APPLICABLE LAWS	Management	For	For
28.	REMOVAL OF THE LIST OF IMPORTANT DECISIONS IN ARTICLE 12.3. OF THE BYLAWS	Management	For	For
29.	DELEGATION TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF AN INCREASE IN THE SHARE CAPITAL WHOSE SUBSCRIPTION WOULD BE RESERVED TO MEMBERS OF A COMPANY SAVINGS PLAN ESTABLISHED PURSUANT TO ARTICLES L. 3332-1 AND FOLLOWING OF THE FRENCH LABOR CODE	Management	For	

## CEPHEID

<b>Security</b>	15670R107	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	CPHD	<b>Meeting Date</b>	04-Nov-2016
<b>Record Date</b>	03-Oct-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1	THE PROPOSAL TO APPROVE THE AGREEMENT AND PLAN OF MERGER, DATED AS OF SEPTEMBER 2, 2016, AS MAY BE AMENDED FROM TIME TO TIME, BY AND AMONG CEPHEID, DANAHER CORPORATION, AND COPPER MERGER SUB, INC., AN INDIRECT, WHOLLY OWNED SUBSIDIARY OF DANAHER, THE MERGER OF COOPER MERGER SUB, INC. WITH AND INTO CEPHEID, WITH .. (DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For
2	THE PROPOSAL TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION THAT WILL OR MAY BECOME PAYABLE TO THE NAMED EXECUTIVE OFFICERS THAT IS BASED ON OR OTHERWISE RELATED TO THE MERGER AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO ITEM 402(T) OF REGULATION S-K IN THE GOLDEN PARACHUTE COMPENSATION TABLE AND THE RELATED NARRATIVE DISCLOSURES.	Management	For	For
3	THE PROPOSAL TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING IF NECESSARY OR APPROPRIATE IN THE VIEW OF THE CEPHEID BOARD OF DIRECTORS TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE SPECIAL MEETING TO APPROVE THE MERGER AGREEMENT, THE MERGER AND THE PRINCIPAL TERMS THEREOF.	Management	For	For

## CIDARA THERAPEUTICS, INC.

<b>Security</b>	171757107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CDTX	<b>Meeting Date</b>	22-Jun-2017
<b>Record Date</b>	25-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DANIEL BURGESS		For	For
	2 THEODORE SCHROEDER		For	For
2.	RATIFICATION OF THE APPOINTMENT OF THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DECEMBER 31, 2017

**CYTOMX THERAPEUTICS, INC.**

<b>Security</b>	23284F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CTMX	<b>Meeting Date</b>	20-Jun-2017
<b>Record Date</b>	28-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF DIRECTOR: NEIL EXTER	Management	For	For
1B.	ELECTION OF DIRECTOR: FREDERICK W. GLUCK	Management	For	For
1C.	ELECTION OF DIRECTOR: MATTHEW P. YOUNG	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**DEPOMED, INC.**

<b>Security</b>	249908104	<b>Meeting Type</b>	Contested-Consent
<b>Ticker Symbol</b>	DEPO	<b>Meeting Date</b>	14-Sep-2016
<b>Record Date</b>	19-Aug-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
01	REQUEST SPECIAL MEETING (FOR = REQUEST MEETING, AGAINST = DO NOT REQUEST MEETING)	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DERMIRA, INC.

<b>Security</b>	24983L104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DERM	<b>Meeting Date</b>	13-Jun-2017
<b>Record Date</b>	19-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 MARK D. MCDADE		For	For
	2 JAKE R. NUNN		For	For
	3 THOMAS G. WIGGANS		For	For
2.	APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION PAID BY US TO OUR NAMED EXECUTIVE OFFICERS FOR THE YEAR ENDED DECEMBER 31, 2016.	Management	For	For
3.	VOTE, ON A NON-BINDING ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
4.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For

DYNAVAX TECHNOLOGIES CORPORATION

<b>Security</b>	268158201	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DVAX	<b>Meeting Date</b>	02-Jun-2017
<b>Record Date</b>	06-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DANIEL L. KISNER, M.D.		For	For
	2 NATALE NAT RICCIARDI		For	For
	3 STANLEY A. PLOTKIN, MD.		For	For
2.	TO AMEND AND RESTATE THE DYNAVAX TECHNOLOGIES CORPORATION 2011 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THAT PLAN BY 1,600,000.	Management	Against	Against
3.	TO AMEND THE DYNAVAX TECHNOLOGIES CORPORATION AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 69,500,000 TO 139,000,000.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
6.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DECEMBER 31, 2017.

5.	TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	1 Year	For
----	---	------------	--------	-----

DYNEX TECHNOLOGIES, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	24-Mar-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	MERGER AGREEMENT AND OTHER TRANSACTIONS CONTEMPLATED THEREBY	Management	For	For
2.	TERMINATION OF STOCKHOLDERS AGREEMENT AND REGISTRATION RIGHTS AGREEMENT	Management	For	For
3.	APPROVAL UNDER SECTION 144 OF THE DGCL	Management	For	For
4.	WAIVER OF APPRAISAL RIGHTS	Management	For	For
5.	ADDITIONAL AGREEMENTS AND ACKNOWLEDGEMENTS	Management	For	For
6.	WAIVER OF NOTICE REQUIREMENTS	Management	For	For
7.	GENERAL AUTHORIZATION	Management	For	For

## DYNEX TECHNOLOGIES, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Mar-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF AMOUNTS PAYABLE TO THE EMPLOYEES PURSUANT TO THE ARRANGEMENTS (AS DESCRIBED IN THE INFORMATION STATEMENT) IN CONNECTION WITH THE PROPOSED TRANSACTION AND OTHER RELATED RESOLUTIONS	Management	For	For

## ENDO INTERNATIONAL PLC

<b>Security</b>	G30401106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ENDP	<b>Meeting Date</b>	08-Jun-2017
<b>Record Date</b>	13-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: ROGER H. KIMMEL	Management	For	For
1B.	ELECTION OF DIRECTOR: PAUL V. CAMPANELLI	Management	For	For
1C.	ELECTION OF DIRECTOR: SHANE M. COOKE	Management	For	For
1D.	ELECTION OF DIRECTOR: NANCY J. HUTSON, PH.D.	Management	For	For
1E.	ELECTION OF DIRECTOR: MICHAEL HYATT	Management	For	For
1F.	ELECTION OF DIRECTOR: DOUGLAS S. INGRAM	Management	For	For
1G.	ELECTION OF DIRECTOR: WILLIAM P. MONTAGUE	Management	For	For
1H.	ELECTION OF DIRECTOR: TODD B. SISITSKY	Management	For	For
1I.	ELECTION OF DIRECTOR: JILL D. SMITH	Management	For	For
2.	TO APPROVE THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO DETERMINE THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM S REMUNERATION.	Management	For	For
3.	TO APPROVE, BY ADVISORY VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
4.	TO APPROVE, BY ADVISORY VOTE, THE FREQUENCY OF FUTURE ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION.	Management	1 Year	For
5.	TO APPROVE THE AMENDMENT OF THE COMPANY S MEMORANDUM OF ASSOCIATION.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

6.	TO APPROVE THE AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION.	Management	For	For
7.	TO APPROVE THE AMENDMENT OF THE COMPANY S AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN.	Management	For	For

**EPIZYME, INC.**

<b>Security</b>	29428V104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EPZM	<b>Meeting Date</b>	22-Jun-2017
<b>Record Date</b>	24-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 ANDREW R ALLEN, MD, PHD		For	For
	2 KENNETH BATE		For	For
	3 ROBERT BAZEMORE		For	For
2.	RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS EPIZYME S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**EUTHYMICS BIOSCIENCE, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	22-May-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	BRIDGE FINANCING	Management	For	For

## EXELIXIS, INC.

<b>Security</b>	30161Q104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EXEL	<b>Meeting Date</b>	24-May-2017
<b>Record Date</b>	31-Mar-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF DIRECTOR: MICHAEL M. MORRISSEY, PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: STELIOS PAPADOPOULOS, PH.D.	Management	For	For
1C.	ELECTION OF DIRECTOR: GEORGE A. SCANGOS, PH.D.	Management	For	For
1D.	ELECTION OF DIRECTOR: LANCE WILLSEY, M.D.	Management	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS EXELIXIS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 29, 2017.	Management	For	For
3.	TO APPROVE THE EXELIXIS, INC. 2017 EQUITY INCENTIVE PLAN.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF EXELIXIS NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
5.	TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF STOCKHOLDER VOTES ON THE COMPENSATION OF EXELIXIS NAMED EXECUTIVE OFFICERS.	Management	1 Year	For

---



## FLAMEL TECHNOLOGIES S.A.

<b>Security</b>	338488109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FLML	<b>Meeting Date</b>	10-Aug-2016
<b>Record Date</b>	24-Jun-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	TO APPROVE THE FLAMEL TECHNOLOGIES S.A. FRENCH STATUTORY FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2015.	Management	For	For
2.	TO APPROVE THE ALLOCATION OF PROFITS FOR THE YEAR ENDED DECEMBER 31, 2015.	Management	For	For
3.	TO RATIFY, ON AN ADVISORY BASIS, THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR U.S. FINANCIAL REPORTING PURPOSES FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For
4.	TO APPOINT A SECOND LEAD STATUTORY AUDITOR AND A SECOND DEPUTY STATUTORY AUDITOR PURSUANT TO ARTICLE L. 823-2 OF THE FRENCH COMMERCIAL CODE.	Management	For	For
5.	TO RENEW MR. MICHAEL S. ANDERSON AS A DIRECTOR.	Management	For	For
6.	TO RENEW MR. GUILLAUME CERUTTI AS A DIRECTOR.	Management	For	For
7.	TO RENEW DR. FRANCIS J.T. FILDES AS A DIRECTOR.	Management	For	For
8.	TO RENEW MR. CHRISTOPHE NAVARRE AS A DIRECTOR.	Management	For	For
9.	TO RENEW THE HONORABLE CRAIG R. STAPLETON AS A DIRECTOR.	Management	For	For
10.	TO RENEW MR. BENOIT VAN ASSCHE AS A DIRECTOR.	Management	For	For
11.	TO APPROVE THE ANNUAL AMOUNT OF DIRECTORS' FEES TO BE PAID TO THE BOARD OF DIRECTORS (JETONS DE PRESENCE).	Management	For	For
12.	TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For
13.	TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR EXECUTIVE COMPENSATION ON AN ANNUAL BASIS.	Shareholder	For	Against
14.	TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR EXECUTIVE COMPENSATION EVERY TWO YEARS.	Management	Against	Against
15.	TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON OUR EXECUTIVE COMPENSATION EVERY THREE YEARS.	Shareholder	Against	For
16.	TO APPROVE AGREEMENTS WITH RELATED PARTIES AS DESCRIBED IN ARTICLE L. 225-38 ET	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

17.	SEQ. OF THE FRENCH COMMERCIAL CODE. TO REVIEW AND APPROVE THE COMMON DRAFT TERMS OF CROSS-BORDER MERGER (THE MERGER AGREEMENT ) PROVIDING FOR A MERGER (THE MERGER ) BY WAY OF ACQUISITION (ABSORPTION) OF THE COMPANY BY ITS WHOLLY OWNED SUBSIDIARY AVADEL PHARMACEUTICALS LIMITED (TO BE RE-REGISTERED IN IRELAND PRIOR TO THE MERGER AS AN IRISH PUBLIC LIMITED COMPANY, OR PLC, AND RENAMED AVADEL PHARMACEUTICALS PLC ( AVADEL PLC )).	Management	For	For
18.	TO GRANT POWERS TO THE BOARD OF DIRECTORS TO TAKE SUCH FURTHER ACTIONS AS MAY BE NECESSARY TO COMPLETE THE MERGER AND THE OTHER TRANSACTIONS CONTEMPLATED BY THE MERGER AGREEMENT, INCLUDING THE POWERS TO FILE, NEGOTIATE, SIGN, AMEND AND PUBLISH ANY DOCUMENT, AGREEMENT OR INSTRUMENT NECESSARY FOR SUCH PURPOSES, AND IN PARTICULAR, TO DRAFT, SIGN AND FILE THE CERTIFICATE OF COMPLIANCE IN RELATION TO THE MERGER IN COMPLIANCE WITH THE FRENCH COMMERCIAL CODE.	Management	For	For
19.	TO APPROVE THE DISSOLUTION WITHOUT LIQUIDATION OF THE COMPANY UNDER THE CONDITION PRECEDENT OF THE COMPLETION OF THE MERGER.	Management	For	For
20.	TO APPROVE THE REDUCTION OF THE SHARE PREMIUM OF AVADEL PLC TO ALLOW THE CREATION OF DISTRIBUTABLE RESERVES OF AVADEL PLC WHICH ARE REQUIRED UNDER IRISH LAW IN ORDER TO ALLOW AVADEL PLC TO MAKE DISTRIBUTIONS AND TO PAY DIVIDENDS AND REPURCHASE OR REDEEM SHARES FOLLOWING COMPLETION OF THE MERGER.	Management	For	For
21.	TO AUTHORIZE THE BOARD OF DIRECTORS TO GRANT UP TO 750,000 FREE SHARES TO EMPLOYEES OF THE COMPANY AND ITS SUBSIDIARIES AS WELL AS TO CORPORATE OFFICERS OF THE COMPANY PURSUANT TO A 2016 FREE SHARES PLAN TO BE ADOPTED BY THE BOARD OF DIRECTORS PURSUANT TO THE SHAREHOLDERS AUTHORIZATION AND THE REVOCATION AND WAIVER OF SHAREHOLDERS PREEMPTIVE SUBSCRIPTION RIGHTS WITH RESPECT TO SUCH SHARES.	Management	For	For
22.	TO AUTHORIZE THE BOARD OF DIRECTORS TO GRANT STOCK OPTIONS TO PURCHASE UP TO 1,500,000 SHARES TO EMPLOYEES OF THE COMPANY AND ITS SUBSIDIARIES AS WELL AS TO CORPORATE OFFICERS OF THE COMPANY PURSUANT TO A 2016 STOCK OPTION PLAN TO BE ADOPTED BY THE BOARD OF DIRECTORS PURSUANT TO THE SHAREHOLDERS AUTHORIZATION AND THE REVOCATION AND WAIVER OF SHAREHOLDERS PREEMPTIVE SUBSCRIPTION RIGHTS WITH RESPECT TO SUCH OPTIONS AND THE UNDERLYING SHARES.	Management	For	For
23.	TO AUTHORIZE THE BOARD OF DIRECTORS TO ISSUE STOCK PURCHASE WARRANTS TO	Management	For	For

	PURCHASE UP TO 350,000 SHARES TO NON-EMPLOYEE DIRECTORS OF THE COMPANY AND ITS SUBSIDIARIES (INCLUDING THE CHAIRMAN OF THE BOARD OF DIRECTORS), AND THE REVOCATION AND WAIVER OF SHAREHOLDERS' PREEMPTIVE SUBSCRIPTION RIGHTS WITH RESPECT TO SUCH WARRANTS AND THE UNDERLYING SHARES.			
24.	TO AUTHORIZE THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL BY ISSUING SHARES RESERVED FOR THE MEMBERS OF A COMPANY SAVINGS PLAN ESTABLISHED IN APPLICATION OF ARTICLES L. 3332-18 ET SEQ. OF THE FRENCH LABOR CODE, AND THE REVOCATION AND WAIVER OF SHAREHOLDERS' PREEMPTIVE SUBSCRIPTION RIGHTS WITH RESPECT TO SUCH SHARES.	Shareholder	Against	For
25.	TO AUTHORIZE THE BOARD OF DIRECTORS OR ANY PERSON DELEGATED BY IT WITH THE POWERS NECESSARY TO CARRY OUT ANY FORMALITIES REQUIRED BY LAW TO GIVE EFFECT TO THE RESOLUTIONS APPROVED AT THE MEETING.	Management	For	For

**FLEX PHARMA INC**

<b>Security</b>	33938A105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FLKS	<b>Meeting Date</b>	01-Jun-2017
<b>Record Date</b>	07-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DIRECTOR	Management		
	1	ROBERT PEREZ	For	For
	2	STUART RANDLE	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

---

## FOAMIX PHARMACEUTICALS LTD

<b>Security</b>	M46135105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOMX	<b>Meeting Date</b>	13-Jul-2017
<b>Record Date</b>	15-Jun-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPOINT KESSELMAN & KESSELMAN (PWC ISRAEL) AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR 2017, AND AUTHORIZE THE BOARD TO DETERMINE THE COMPENSATION OF THE AUDITORS.	Management	For	For
2.	RATIFY THE ELECTION OF DR. DALIA MEGIDDO AS A DIRECTOR OF THE COMPANY.	Management	For	For
3.	APPROVE THE TERMS OF COMPENSATION OF DR. STANLEY HIRSCH, OUR CHAIRMAN OF THE BOARD OF DIRECTORS, FOR THE YEAR 2016 AND ONWARD.	Management	For	For
4.	APPROVE THE AWARD OF ADDITIONAL OPTIONS AND RESTRICTED SHARE UNITS TO THE COMPANY'S NON- EXECUTIVE DIRECTORS.	Management	For	For
5.	APPROVE AN INCREASE OF THE AUTHORIZED SHARE CAPITAL OF THE COMPANY BY AN ADDITIONAL NIS 6,400,000 DIVIDED INTO 40,000,000 ORDINARY SHARES WITH A NOMINAL VALUE OF NIS 0.16 PER SHARE.	Management	Abstain	Against

## GALAPAGOS N V

<b>Security</b>	36315X101	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	26-Jul-2016
<b>Record Date</b>	08-Jul-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
S1.	TO APPOINT MS. MARY KERR AS AN INDEPENDENT DIRECTOR OF THE COMPANY.	Management	For	
E2.	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 40% OF THE SHARE CAPITAL.	Management	For	

## GALAPAGOS N V

<b>Security</b>	36315X101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	25-Apr-2017

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Record Date 20-Mar-2017

Item	Proposal	Proposed by	Vote	For/Against Mgmt
O2	COMMUNICATION AND APPROVAL OF THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2016 AND APPROVAL OF THE ALLOCATION OF THE ANNUAL RESULT AS PROPOSED BY THE BOARD OF DIRECTORS.	Management	For	
O5	COMMUNICATION AND APPROVAL OF THE REMUNERATION REPORT.	Management	For	
O6	RELEASE FROM LIABILITY TO BE GRANTED TO THE DIRECTORS AND THE STATUTORY AUDITOR FOR THE PERFORMANCE OF THEIR DUTIES IN THE COURSE OF THE FINANCIAL YEAR ENDED 31 DECEMBER 2016.	Management	For	
O7	RATIFICATION OF THE STATUTORY AUDITOR S REMUNERATION FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2016.	Management	For	
O8	RE-APPOINTMENT OF STATUTORY AUDITOR AND DETERMINATION OF STATUTORY AUDITOR S REMUNERATION.	Management	For	
O9A	RE-APPOINTMENT OF MR. ONNO VAN DE STOLPE AS DIRECTOR OF THE COMPANY.	Management	For	
O9B	RE-APPOINTMENT OF DR. RAJ PAREKH AS DIRECTOR OF THE COMPANY.	Management	For	
O9C	RE-APPOINTMENT OF MS. KATRINE BOSLEY AS INDEPENDENT DIRECTOR OF THE COMPANY.	Management	For	
O10	REMUNERATION OF DIRECTORS.	Management	For	
O11	OFFER OF WARRANTS.	Management	For	
O12	APPLICATION OF ARTICLE 556 OF THE BELGIAN COMPANIES CODE.	Management	For	
E2	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 20% OF THE SHARE CAPITAL.	Management	For	
E3	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 33% OF THE SHARE CAPITAL, IN SPECIFIC CIRCUMSTANCES.	Management	For	

**GALAPAGOS NV**

<b>Security</b>	B44170106	<b>Meeting Type</b>	ExtraOrdinary General Meeting
<b>Ticker Symbol</b>	GLPG NA	<b>Meeting Date</b>	26-Jul-2016
<b>Record Date</b>	12-Jul-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
S.1	ELECT MARY KERR AS DIRECTOR	Management	For	
E.1	RECEIVE SPECIAL BOARD REPORT RE: ITEM 2	Non-Voting		
E.2	RENEW AUTHORIZATION TO INCREASE SHARE CAPITAL WITHIN THE FRAMEWORK OF AUTHORIZED CAPITAL	Management	For	

---

## GALAPAGOS NV

<b>Security</b>	B44170106	<b>Meeting Type</b>	MIX
<b>Ticker Symbol</b>	GLPG NA	<b>Meeting Date</b>	25-Apr-2017
<b>Record Date</b>	11-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
O.1	RECEIVE DIRECTORS AND AUDITORS REPORTS	Non-Voting		
O.2	APPROVE FINANCIAL STATEMENTS AND ALLOCATION OF INCOME	Management	For	For
O.3	RECEIVE AUDITORS REPORTS	Non-Voting		
O.4	RECEIVE CONSOLIDATED FINANCIAL STATEMENTS AND STATUTORY REPORTS	Non-Voting		
O.5	APPROVE REMUNERATION REPORT	Management	For	For
O.6	APPROVE DISCHARGE OF DIRECTORS AND AUDITORS	Management	For	For
O.7	APPROVE REMUNERATION OF AUDITORS	Management	For	For
O.8	RATIFY DELOITTE AS AUDITORS	Management	For	For
O.9.I	RE-ELECT ONNO VAN STOLPE AS DIRECTOR	Management	For	For
O.9.II	RE-ELECT RAJ PAREKH AS DIRECTOR	Management	For	For
O.9.III	RE-ELECT KATRINE BOSLEY AS INDEPENDENT DIRECTOR	Management	For	For
O.10	APPROVE REMUNERATION OF DIRECTORS	Management	For	For
O.11	APPROVE GALAPAGOS WARRANT PLAN 2017	Management	For	For
O.12	APPROVE CHANGE OF CONTROL CLAUSE	Management	For	For
O.13	TRANSACT OTHER BUSINESS	Non-Voting		
E.1	RECEIVE SPECIAL BOARD REPORT RE: AUTHORIZATION TO INCREASE CAPITAL	Non-Voting		
E.2	RENEW AUTHORIZATION TO INCREASE SHARE CAPITAL WITHIN THE FRAMEWORK OF AUTHORIZED CAPITAL UP TO 20 PERCENT OF THE SHARE CAPITAL	Management	For	For
E.3	RENEW AUTHORIZATION TO INCREASE SHARE CAPITAL WITHIN THE FRAMEWORK OF AUTHORIZED CAPITAL UP TO 33 PERCENT OF THE SHARE CAPITAL	Management	For	For



## GENMARK DIAGNOSTICS, INC.

<b>Security</b>	372309104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GNMK	<b>Meeting Date</b>	25-May-2017
<b>Record Date</b>	29-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DARYL J. FAULKNER		For	For
	2 JAMES FOX, PH.D.		For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
4.	TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY WITH WHICH THE COMPANY SHOULD HOLD FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	1 Year	For

## GENOMEDX BIOSCIENCES INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Jan-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	AUTHORIZED SHARE STRUCTURE AMENDMENT RESOLUTION	Management	For	For
2.	SPECIAL RIGHTS AND RESTRICTIONS RESOLUTION	Management	For	For
3.	CLASS C PREFERRED SHARE ISSUANCE RESOLUTION	Management	For	For

## GENOMEDX BIOSCIENCES INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	30-Jun-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	AUDITOR RESOLUTION	Management	For	For
2.	ELECTION OF DIRECTORS	Management	For	For
3.	AMENDMENTS TO STOCK OPTION PLAN	Management	For	For

## GILEAD SCIENCES, INC.

<b>Security</b>	375558103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GILD	<b>Meeting Date</b>	10-May-2017
<b>Record Date</b>	16-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: JOHN F. COGAN, PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: KELLY A. KRAMER	Management	For	For
1C.	ELECTION OF DIRECTOR: KEVIN E. LOFTON	Management	For	For
1D.	ELECTION OF DIRECTOR: JOHN C. MARTIN, PH.D.	Management	For	For
1E.	ELECTION OF DIRECTOR: JOHN F. MILLIGAN, PH.D.	Management	For	For
1F.	ELECTION OF DIRECTOR: NICHOLAS G. MOORE	Management	For	For
1G.	ELECTION OF DIRECTOR: RICHARD J. WHITLEY, M.D.	Management	For	For
1H.	ELECTION OF DIRECTOR: GAYLE E. WILSON	Management	For	For
1I.	ELECTION OF DIRECTOR: PER WOLD-OLSEN	Management	For	For
2.	RATIFICATION OF THE SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.	Management	For	For
3.	RESTATEMENT OF THE GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN.	Management	For	For
4.	ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	ADVISORY VOTE AS TO THE FREQUENCY OF FUTURE ADVISORY SHAREHOLDER VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For
6.	STOCKHOLDER PROPOSAL REQUESTING THAT THE BOARD TAKE STEPS TO PERMIT STOCKHOLDER ACTION BY WRITTEN CONSENT.	Shareholder	Against	For
7.	STOCKHOLDER PROPOSAL REQUESTING THAT THE BOARD ADOPT A POLICY THAT THE CHAIRMAN OF THE BOARD OF DIRECTORS BE AN INDEPENDENT DIRECTOR.	Shareholder	Against	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

GLOBAL BLOOD THERAPEUTICS, INC.

<b>Security</b>	37890U108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GBT	<b>Meeting Date</b>	20-Jun-2017
<b>Record Date</b>	21-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DIRECTOR	Management		
	1	WILLIE L. BROWN, JR.	For	For
	2	PHILIP A. PIZZO, M.D.	For	For
2.	TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## HALOZYME THERAPEUTICS, INC.

<b>Security</b>	40637H109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	HALO	<b>Meeting Date</b>	04-May-2017
<b>Record Date</b>	09-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 KENNETH J. KELLEY		For	For
	2 MATTHEW L. POSARD		For	For
2.	TO APPROVE, BY A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO APPROVE, BY A NON-BINDING ADVISORY VOTE, THE FREQUENCY OF EXECUTIVE COMPENSATION STOCKHOLDER VOTES.	Management	1 Year	For
4.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## IDEXX LABORATORIES, INC.

<b>Security</b>	45168D104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IDXX	<b>Meeting Date</b>	03-May-2017
<b>Record Date</b>	10-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: REBECCA M. HENDERSON, PHD	Management	For	For
1B.	ELECTION OF DIRECTOR: LAWRENCE D. KINGSLEY	Management	For	For
1C.	ELECTION OF DIRECTOR: SOPHIE V. VANDEBROEK, PHD	Management	For	For
2.	RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT FISCAL YEAR (PROPOSAL TWO).	Management	For	For
3.	ADVISORY VOTE ON EXECUTIVE COMPENSATION. TO APPROVE A NONBINDING ADVISORY RESOLUTION ON THE COMPANY S EXECUTIVE COMPENSATION (PROPOSAL THREE).	Management	For	For
4.	ADVISORY VOTE ON THE FREQUENCY OF ADVISORY VOTES ON EXECUTIVE COMPENSATION. TO RECOMMEND, BY NONBINDING ADVISORY VOTE, THE FREQUENCY	Management	1 Year	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

OF FUTURE ADVISORY VOTES ON THE  
COMPANY'S EXECUTIVE COMPENSATION  
(PROPOSAL FOUR).

ILLUMINA, INC.

<b>Security</b>	452327109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ILMN	<b>Meeting Date</b>	30-May-2017
<b>Record Date</b>	07-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: CAROLINE D. DORSA	Management	For	For
1B.	ELECTION OF DIRECTOR: ROBERT S. EPSTEIN, M.D.	Management	For	For
1C.	ELECTION OF DIRECTOR: PHILIP W. SCHILLER	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4.	TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF EXECUTIVE COMPENSATION VOTES.	Management	1 Year	For
5.	TO APPROVE AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO REMOVE CERTAIN SUPERMAJORITY VOTING REQUIREMENTS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For

**ILLUMINOS MEDICAL, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	28-Mar-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	CONVERTIBLE NOTE FINANCING	Management	For	For
2.	ANTI-DILUTION	Management	For	For
3.	GENERAL RESOLUTIONS	Management	For	For

**IMPAX LABORATORIES, INC.**

<b>Security</b>	45256B101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IPXL	<b>Meeting Date</b>	16-May-2017
<b>Record Date</b>	27-Mar-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF DIRECTOR: LESLIE Z. BENET, PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: RICHARD A. BIERLY	Management	For	For
1C.	ELECTION OF DIRECTOR: PAUL M. BISARO	Management	For	For
1D.	ELECTION OF DIRECTOR: J. KEVIN BUCHI	Management	For	For
1E.	ELECTION OF DIRECTOR: ROBERT L. BURR	Management	For	For
1F.	ELECTION OF DIRECTOR: ALLEN CHAO, PH.D.	Management	For	For
1G.	ELECTION OF DIRECTOR: MARY K. PENDERGAST, J.D.	Management	For	For
1H.	ELECTION OF DIRECTOR: PETER R. TERRERI	Management	For	For
1I.	ELECTION OF DIRECTOR: JANET S. VERGIS	Management	For	For
2.	TO APPROVE THE A&R OF OUR NON-QUALIFIED ESPP ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)	Management	For	For
3.	TO APPROVE THE FOURTH A&R OF OUR 2002 EQUITY INCENTIVE PLAN ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)	Management	For	For
4.	TO APPROVE, BY NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
5.	TO APPROVE, BY NON-BINDING VOTE, THE FREQUENCY OF NAMED EXECUTIVE OFFICER COMPENSATION VOTES.	Management	1 Year	For
6.	TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)	Management	For	For

**INCYTE CORPORATION**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	45337C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INCY	<b>Meeting Date</b>	26-May-2017
<b>Record Date</b>	07-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 JULIAN C. BAKER		For	For
	2 JEAN-JACQUES BIENAIME		For	For
	3 PAUL A. BROOKE		For	For
	4 PAUL J. CLANCY		For	For
	5 WENDY L. DIXON		For	For
	6 PAUL A. FRIEDMAN		For	For
	7 HERVE HOPPENOT		For	For
2.	TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE FREQUENCY OF FUTURE NON-BINDING ADVISORY STOCKHOLDER VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	1 Year	For
4.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2017.	Management	For	For

## INNOVIVA INC

<b>Security</b>	45781M101	<b>Meeting Type</b>	Contested-Annual
<b>Ticker Symbol</b>	INVA	<b>Meeting Date</b>	20-Apr-2017
<b>Record Date</b>	24-Feb-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	MICHAEL W. AGUIAR	For	For
	2	BARBARA DUNCAN	For	For
	3	CATHERINE J. FRIEDMAN	For	For
	4	PATRICK G. LEPORE	For	For
	5	PAUL A. PEPE	For	For
	6	JAMES L. TYREE	For	For
	7	WILLIAM H. WALTRIP	For	For
2.	APPROVE AN ADVISORY NON-BINDING RESOLUTION REGARDING EXECUTIVE COMPENSATION.	Management	For	For
3.	APPROVE AN ADVISORY NON-BINDING RESOLUTION ON THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	1 Year	For
4.	RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
5.	VOTE ON A STOCKHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE ANNUAL MEETING, TO REPEAL CERTAIN PROVISIONS OF THE COMPANY'S BYLAWS.	Shareholder	For	Against

## INTELLIA THERAPEUTICS, INC.

<b>Security</b>	45826J105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NTLA	<b>Meeting Date</b>	18-May-2017
<b>Record Date</b>	04-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF CLASS I DIRECTOR: NESSAN BIRMINGHAM, PH.D.	Management	For	For
1B.	ELECTION OF CLASS I DIRECTOR: JEAN-FRANCOIS FORMELA, M.D.	Management	For	For
2.	RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS INTELLIA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	RATIFICATION OF THE AMENDED AND RESTATED 2015 STOCK OPTION AND INCENTIVE PLAN.	Management	For	For





## JAZZ PHARMACEUTICALS PLC

<b>Security Ticker Symbol Record Date</b>	G50871105 JAZZ 07-Jun-2016	<b>Meeting Type Meeting Date</b>	Annual 04-Aug-2016
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: PAUL L. BERNS	Management	For	For
1B.	ELECTION OF DIRECTOR: PATRICK G. ENRIGHT	Management	For	For
1C.	ELECTION OF DIRECTOR: SEAMUS MULLIGAN	Management	For	For
1D.	ELECTION OF DIRECTOR: NORBERT G. RIEDEL, PH.D.	Management	For	For
2.	TO RATIFY, ON A NON-BINDING ADVISORY BASIS, THE APPOINTMENT OF KPMG, DUBLIN AS THE INDEPENDENT AUDITORS OF JAZZ PHARMACEUTICALS PLC FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS REMUNERATION.	Management	For	For
3.	TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF JAZZ PHARMACEUTICALS PLC S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4A.	TO APPROVE AMENDMENTS TO JAZZ PHARMACEUTICALS PLC S MEMORANDUM OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE ADJUSTMENTS TO ADDRESS THE ENACTMENT OF THE IRISH COMPANIES ACT 2014 AND A MINOR HOUSEKEEPING MATTER.	Management	For	For
4B.	TO APPROVE AMENDMENTS TO JAZZ PHARMACEUTICALS PLC S ARTICLES OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE ADJUSTMENTS TO ADDRESS THE ENACTMENT OF THE IRISH COMPANIES ACT 2014 AND CERTAIN MINOR HOUSEKEEPING MATTERS.	Management	For	For
5.	TO AUTHORIZE JAZZ PHARMACEUTICALS PLC AND/OR ANY SUBSIDIARY OF JAZZ PHARMACEUTICALS PLC TO MAKE OPEN MARKET PURCHASES OF JAZZ PHARMACEUTICALS PLC S ORDINARY SHARES.	Management	For	For
6.	TO RENEW THE BOARD OF DIRECTORS EXISTING AUTHORITY UNDER IRISH LAW TO ALLOT AND ISSUE ORDINARY SHARES.	Management	For	For
7.	TO RENEW THE BOARD OF DIRECTORS EXISTING AUTHORITY UNDER IRISH LAW TO ALLOT AND ISSUE ORDINARY SHARES FOR CASH WITHOUT FIRST OFFERING THOSE ORDINARY SHARES TO EXISTING SHAREHOLDERS PURSUANT TO THE STATUTORY PRE-EMPTION RIGHT THAT WOULD OTHERWISE APPLY.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

8.	TO APPROVE ANY MOTION TO ADJOURN THE ANNUAL MEETING, OR ANY ADJOURNMENTS THEREOF, TO ANOTHER TIME AND PLACE TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE ANY OR ALL OF PROPOSALS 4A, 4B AND/OR 7.	Management	For	For
9.	TO APPROVE AN AMENDMENT AND RESTATEMENT OF JAZZ PHARMACEUTICALS PLC S 2011 EQUITY INCENTIVE PLAN IN ORDER TO RENEW JAZZ PHARMACEUTICALS PLC S ABILITY TO GRANT AWARDS THEREUNDER THAT MAY QUALIFY AS PERFORMANCE-BASED COMPENSATION UNDER SECTION 162(M) OF THE U.S. INTERNAL REVENUE CODE.	Management	For	For
10.	TO APPROVE AN AMENDMENT AND RESTATEMENT OF JAZZ PHARMACEUTICALS PLC S AMENDED AND RESTATED 2007 NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN IN ORDER TO (I) EXPAND THE TYPES OF STOCK AWARDS THAT MAY BE GRANTED THEREUNDER TO JAZZ PHARMACEUTICALS PLC S NON-EMPLOYEE DIRECTORS AND (II) ELIMINATE THE FINAL AUTOMATIC ANNUAL INCREASE TO THE SHARE RESERVE THAT IS OTHERWISE SCHEDULED TO OCCUR IN 2017 PURSUANT TO THE EVERGREEN PROVISION INCLUDED THEREIN.	Management	For	For

## JAZZ PHARMACEUTICALS PLC

<b>Security</b>	G50871105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JAZZ	<b>Meeting Date</b>	03-Aug-2017
<b>Record Date</b>	07-Jun-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: BRUCE C. COZADD	Management	For	For
1B.	ELECTION OF DIRECTOR: HEATHER ANN MCSHARRY	Management	For	For
1C.	ELECTION OF DIRECTOR: RICK E WINNINGHAM	Management	For	For
2.	TO RATIFY, ON A NON-BINDING ADVISORY BASIS, THE APPOINTMENT OF KPMG, DUBLIN AS THE INDEPENDENT AUDITORS OF JAZZ PHARMACEUTICALS PLC FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS REMUNERATION.	Management	For	For
3.	TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF JAZZ PHARMACEUTICALS PLC S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4.	TO AUTHORIZE JAZZ PHARMACEUTICALS PLC AND/OR ANY SUBSIDIARY OF JAZZ PHARMACEUTICALS PLC TO MAKE OPEN MARKET PURCHASES OF JAZZ PHARMACEUTICALS PLC S ORDINARY SHARES.	Management	For	For

## KARYOPHARM THERAPEUTICS INC.

<b>Security</b>	48576U106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	KPTI	<b>Meeting Date</b>	15-Jun-2017
<b>Record Date</b>	18-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 J. SCOTT GARLAND		For	For
	2 BARRY E. GREENE		For	For
	3 MANSOOR RAZA MIRZA, MD.		For	For
2.	RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## MEDIVATION, INC.

<b>Security</b>	58501N101	<b>Meeting Type</b>	Contested-Consent
<b>Ticker Symbol</b>	MDVN	<b>Meeting Date</b>	06-Jul-2016
<b>Record Date</b>	01-Jun-2016		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
01	THAT ANY CHANGES TO THE AMENDED AND RESTATED BYLAWS OF THE COMPANY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 13, 2015 (THE MEDIVATION BYLAWS ) BE REPEALED; A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
02	THAT SECTION 17(A) OF ARTICLE IV OF THE MEDIVATION BYLAWS BE AMENDED TO EXPRESSLY PROVIDE THAT ANY VACANCIES ON THE BOARD OF DIRECTORS OF MEDIVATION (THE BOARD ) MAY BE FILLED BY THE STOCKHOLDERS OF THE COMPANY AND THOSE VACANCIES ON THE BOARD RESULTING FROM A REMOVAL OF DIRECTORS BY THE STOCKHOLDERS SHALL BE FILLED EXCLUSIVELY BY THE STOCKHOLDERS. A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3A	REMOVAL OF DIRECTOR: KIM D. BLICKENSTAFF A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3B	REMOVAL OF DIRECTOR: KATHRYN E. FALBERG A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3C	REMOVAL OF DIRECTOR: DAVID T. HUNG A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3D	REMOVAL OF DIRECTOR: MICHAEL L. KING A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3E	REMOVAL OF DIRECTOR: C. PATRICK MACHADO A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3F	REMOVAL OF DIRECTOR: DAWN SVORONOS A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3G	REMOVAL OF DIRECTOR: W. ANTHONY VERNON A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
3H	REMOVAL OF DIRECTOR: WENDY L. YARNO A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4A	ELECTION OF DIRECTOR: MICHAEL E. CAMPBELL A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4B	ELECTION OF DIRECTOR: BARBARA DEPTULA A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

4C	ELECTION OF DIRECTOR: WENDY E. LANE A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4D	ELECTION OF DIRECTOR: RONALD S. ROLFE A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4E	ELECTION OF DIRECTOR: STEVEN J. SHULMAN A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4F	ELECTION OF DIRECTOR: CHARLES P. SLACIK A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4G	ELECTION OF DIRECTOR: JAMES L. TYREE A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For
4H	ELECTION OF DIRECTOR: DAVID A. WILSON A FOR OR ABSTAIN VOTE IS A VOTE TO REVOKE CONSENT	Management	For	For

---

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MERUS N.V.

<b>Security Ticker Symbol Record Date</b>	N5749R100 MRUS 26-Apr-2017	<b>Meeting Type Meeting Date</b>	Annual 24-May-2017
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	ADOPTION OF THE ANNUAL ACCOUNTS OVER THE FINANCIAL YEAR 2016	Management	For	For
2.	APPOINTMENT OF THE EXTERNAL AUDITOR FOR THE FINANCIAL YEAR 2017	Management	For	For
3.	RELEASE OF THE MANAGEMENT DIRECTORS FROM LIABILITY FOR THE EXERCISE OF THEIR DUTIES DURING THE FINANCIAL YEAR 2016	Management	For	For
4.	RELEASE OF THE SUPERVISORY DIRECTORS FROM LIABILITY FOR THE EXERCISE OF THEIR DUTIES DURING THE FINANCIAL YEAR 2016	Management	For	For
5.	(I) AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION, (II) AUTHORIZATION TO IMPLEMENT SUCH AMENDMENT AND (III) DESIGNATION OF MANAGING AND SUPERVISORY DIRECTORS AS EXECUTIVE AND NON-EXECUTIVE DIRECTORS	Management	For	For
6.	REAPPOINTMENT OF DR. W. BERTHOLD, PH.D. AND DESIGNATION AS NON-EXECUTIVE DIRECTOR	Management	For	For
7.	REAPPOINTMENT OF DR. J.P. DE KONING, PH.D. AND DESIGNATION AS NON-EXECUTIVE DIRECTOR	Management	For	For
8.	AMENDMENT OF THE COMPANY S COMPENSATION POLICY	Management	For	For
9.	AMENDMENT OF THE COMPANY S SUPERVISORY BOARD MEMBER COMPENSATION PROGRAM	Management	For	For
10.	APPROVAL OF THE INCREASE OF THE GRANT DATE FAIR VALUE OF EQUITY AWARDS UNDER THE COMPANY S SUPERVISORY BOARD MEMBER COMPENSATION PROGRAM	Management	For	For
11.	GRANTING OF EQUITY COMPENSATION TO MR. M.T. IWICKI	Management	For	For
12.	GRANTING OF EQUITY COMPENSATION TO DR. W. BERTHOLD, PH.D.	Management	For	For
13.	GRANTING OF EQUITY COMPENSATION TO MR. L.M.S. CARNOT	Management	For	For
14.	GRANTING OF EQUITY COMPENSATION TO DR. J.P. DE KONING, PH.D.	Management	For	For
15.	GRANTING OF EQUITY COMPENSATION TO DR. A. MEHRA, M.D.	Management	For	For
16.	GRANTING OF EQUITY COMPENSATION TO MR. G.D. PERRY	Management	For	For
17.	APPROVAL OF AMENDMENT TO AWARDS GRANTED UNDER THE COMPANY S 2010 EMPLOYEE OPTION PLAN	Management	For	For
18.	GRANTING AUTHORIZATION OF THE MANAGEMENT BOARD TO ISSUE SHARES AND TO	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

19.	GRANT RIGHTS TO SUBSCRIBE FOR SHARES GRANTING AUTHORIZATION OF THE MANAGEMENT BOARD TO LIMIT OR EXCLUDE PRE-EMPTION RIGHTS	Management	For	For
20.	GRANTING AUTHORIZATION OF THE MANAGEMENT BOARD TO ACQUIRE SHARES IN THE COMPANY S CAPITAL	Management	For	For

**MOMENTA PHARMACEUTICALS, INC.**

<b>Security</b>	60877T100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MNTA	<b>Meeting Date</b>	20-Jun-2017
<b>Record Date</b>	24-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: BRUCE L. DOWNEY	Management	For	For
1B.	ELECTION OF DIRECTOR: COREY N. FISHMAN	Management	For	For
1C.	ELECTION OF DIRECTOR: GEORGES GEMAYEL	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	1 Year	For
5.	TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE MOMENTA PHARMACEUTICALS, INC. 2013 INCENTIVE AWARD PLAN, WHICH, AMONG OTHER THINGS, INCREASES THE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE BY 4,300,000 SHARES.	Management	For	For
6.	TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE MOMENTA PHARMACEUTICALS, INC. 2004 EMPLOYEE STOCK PURCHASE PLAN, WHICH INCREASES THE NUMBER OF SHARES AUTHORIZED FOR ISSUANCE BY 1,400,000 SHARES.	Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MYLAN N.V.

<b>Security</b>	N59465109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MYL	<b>Meeting Date</b>	22-Jun-2017
<b>Record Date</b>	25-May-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: HEATHER BRESCH	Management	Against	Against
1B.	ELECTION OF DIRECTOR: WENDY CAMERON	Management	Against	Against
1C.	ELECTION OF DIRECTOR: HON. ROBERT J. CINDRICH	Management	For	For
1D.	ELECTION OF DIRECTOR: ROBERT J. COURY	Management	Against	Against
1E.	ELECTION OF DIRECTOR: JOELLEN LYONS DILLON	Management	For	For
1F.	ELECTION OF DIRECTOR: NEIL DIMICK, C.P.A.	Management	Against	Against
1G.	ELECTION OF DIRECTOR: MELINA HIGGINS	Management	For	For
1H.	ELECTION OF DIRECTOR: RAJIV MALIK	Management	For	For
1I.	ELECTION OF DIRECTOR: MARK W. PARRISH	Management	Against	Against
1J.	ELECTION OF DIRECTOR: RANDALL L. (PETE) VANDERVEEN, PH.D., R.PH.	Management	For	For
1K.	ELECTION OF DIRECTOR: SJOERD S. VOLLEBREGT	Management	For	For
2.	ADOPTION OF THE DUTCH ANNUAL ACCOUNTS FOR FISCAL YEAR 2016	Management	For	For
3.	RATIFICATION OF THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2017	Management	For	For
4.	INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. FOR THE AUDIT OF THE COMPANY S DUTCH STATUTORY ANNUAL ACCOUNTS FOR FISCAL YEAR 2017	Management	For	For
5.	APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY (THE SAY-ON-PAY VOTE )	Management	Against	Against
6.	ADVISORY VOTE ON THE FREQUENCY OF THE SAY-ON-PAY VOTE	Management	1 Year	For
7.	AUTHORIZATION OF THE MYLAN BOARD TO ACQUIRE ORDINARY SHARES AND PREFERRED SHARES IN THE CAPITAL OF THE COMPANY	Management	For	For

NANOSTRING TECHNOLOGIES, INC.

<b>Security</b>	63009R109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NSTG	<b>Meeting Date</b>	21-Jun-2017
<b>Record Date</b>	24-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	R. BRADLEY GRAY		For	For
2	R.M. HERSHBERG, MD, PHD		For	For
3	KIRK D. MALLOY, PH.D.		For	For
2.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**NATERA, INC.**

<b>Security</b>	632307104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NTRA	<b>Meeting Date</b>	23-May-2017
<b>Record Date</b>	31-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 HERM ROSENMAN		For	For
	2 JOHN STEUART		For	For
	3 JONATHAN SHEENA		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## NEUROCRINE BIOSCIENCES, INC.

<b>Security</b>	64125C109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NBIX	<b>Meeting Date</b>	22-May-2017
<b>Record Date</b>	31-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 KEVIN C. GORMAN, PH.D.		For	For
	2 GARY A. LYONS		For	For
	3 A W SANDROCK JR MD, PHD		For	For
2.	ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	AN ADVISORY VOTE ON THE FREQUENCY OF ADVISORY VOTING ON THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	1 Year	For
4.	TO APPROVE AN AMENDMENT TO THE COMPANY S 2011 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER FROM 15,500,000 TO 17,000,000.	Management	For	For
5.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	05-Aug-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	ENGAGEMENT LETTER WITH JEFFERIES	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	08-Aug-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	BRIDGE FINANCING	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	17-Nov-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	BRIDGE FINANCING	Management	For	For

NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	16-Dec-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	BRIDGE FINANCING	Management	For	For
2.	SERVICE PROVIDER CONVERTIBLE NOTE	Management	For	For
3.	INTERCOMPANY ADJUSTMENTS	Management	For	For

---

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	16-Dec-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	EMPLOYMENT AND OPTION AGREEMENTS	Management	For	For
2.	AMENDING CHARTER AND INCENTIVE STOCK PLAN EXPANSION	Management	For	For
3.	ADDING MR. BRIAN GOFF TO BOARD OF DIRECTORS	Management	For	For
4.	AMENDING CHARTER AND INCENTIVE STOCK PLAN EXPANSION	Management	For	For
5.	GENERAL; IMPLEMENTATION	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	14-Feb-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	BRIDGE FINANCING	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	09-Mar-2017
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DECLARATION OF DIVIDEND	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	13-Mar-2017
<b>Record Date</b>	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF POTENTIAL PARACHUTE PAYMENTS TO EXECUTIVES	Management	For	For

NEUROVANCE, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	13-Mar-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF MERGER AGREEMENT AND RELATED DOCUMENTS	Management	For	For
2.	APPROVAL OF SECURITYHOLDERS REPRESENTATIVE	Management	For	For
3.	TERMINATION OF STOCKHOLDER AGREEMENTS	Management	For	For
4.	WAIVER OF APPRAISAL RIGHTS	Management	For	For
5.	GENERAL AUTHORITY	Management	For	For

NOVAVAX, INC.

Security	670002104	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	15-Jun-2017
Record Date	19-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 STANLEY C. ERCK		For	For
	2 RAJIV I. MODI		For	For
2.	TO CONSIDER AND VOTE WHETHER TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO CONSIDER AND VOTE, ON AN ADVISORY BASIS, HOLDING FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES EVERY THREE YEARS, EVERY TWO YEARS, OR EVERY YEAR.	Management	1 Year	Against
4.	TO AMEND AND RESTATE THE NOVAVAX, INC. AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN AND TO INCREASE THE NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01, AVAILABLE FOR ISSUANCE THEREUNDER BY 5,000,000 SHARES.	Management	For	For
5.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## OVID THERAPEUTICS INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	04-Jan-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	APPROVAL OF ISSUANCE OF SERIES B-1 PREFERRED STOCK	Management	For	For
2.	AMENDMENT AND RESTATEMENT OF THE CERTIFICATE OF INCORPORATION	Management	For	For
3.	GENERAL	Management	For	For

## OVID THERAPEUTICS INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - REVERSE STOCK SPLIT	Management	For	For
2.	INDEMNITY AGREEMENTS	Management	For	For
3.	GENERAL	Management	For	For

## OVID THERAPEUTICS INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Apr-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	IPO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
2.	APPROVAL OF 2017 EQUITY INCENTIVE PLAN	Management	For	For
3.	APPROVAL OF 2017 EMPLOYEE STOCK PURCHASE PLAN	Management	For	For
4.	GENERAL	Management	For	For

## PARATEK PHARMACEUTICALS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	699374302	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PRTK	<b>Meeting Date</b>	15-Jun-2017
<b>Record Date</b>	17-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.	DIRECTOR	Management		
	1 MICHAEL F. BIGHAM		For	For
	2 ROBERT S. RADIE		For	For
2.	TO CONSIDER AND APPROVE A NON-BINDING ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO HOLD A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF HOLDING FUTURE NON-BINDING ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	3 Years	For
4.	TO CONSIDER AND APPROVE THE PARATEK PHARMACEUTICALS, INC. ANNUAL INCENTIVE PLAN.	Management	For	For
5.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For



## PIERIS PHARMACEUTICALS INC

<b>Security</b>	720795103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PIRS	<b>Meeting Date</b>	30-Jun-2017
<b>Record Date</b>	08-May-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	STEPHEN S. YODER	For	For
	2	MICHAEL RICHMAN	For	For
2.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## RA PHARMACEUTICALS, INC.

<b>Security</b>	74933V108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARX	<b>Meeting Date</b>	20-Jun-2017
<b>Record Date</b>	25-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	DOUGLAS A. TRECO, PH.D.	For	For
	2	EDWARD T. MATHERS	For	For
2.	TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

## REGENERON PHARMACEUTICALS, INC.

<b>Security</b>	75886F107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	REGN	<b>Meeting Date</b>	09-Jun-2017
<b>Record Date</b>	13-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.1	ELECTION OF DIRECTOR: BONNIE L. BASSLER	Management	For	For
1.2	ELECTION OF DIRECTOR: N. ANTHONY COLES	Management	For	For
1.3	ELECTION OF DIRECTOR: JOSEPH L. GOLDSTEIN	Management	For	For
1.4	ELECTION OF DIRECTOR: CHRISTINE A. POON	Management	For	For
1.5	ELECTION OF DIRECTOR: P. ROY VAGELOS	Management	For	For
1.6	ELECTION OF DIRECTOR: HUDA Y. ZOGHBI	Management	For	For
2		Management	For	For

RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.				
3	PROPOSAL TO APPROVE THE AMENDED AND RESTATED REGENERON PHARMACEUTICALS, INC. 2014 LONG-TERM INCENTIVE PLAN	Management	For	For
4	PROPOSAL TO APPROVE, ON AN ADVISORY BASIS, EXECUTIVE COMPENSATION.	Management	For	For
5	PROPOSAL TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	3 Years	For

---

**RETROPHIN, INC.**

<b>Security</b>	761299106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RTRX	<b>Meeting Date</b>	17-May-2017
<b>Record Date</b>	20-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	STEPHEN ASELAGÉ	For	For
	2	TIMOTHY COUGHLIN	For	For
	3	ROY BAYNES	For	For
	4	JOHN KOZARICH	For	For
	5	GARY LYONS	For	For
	6	JEFFREY MECKLER	For	For
	7	JOHN A. ORWIN	For	For
	8	RON SQUARER	For	For
2.	TO APPROVE THE COMPANY'S 2015 EQUITY INCENTIVE PLAN, AS AMENDED, TO, AMONG OTHER ITEMS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER BY 1,800,000.	Management	For	For
3.	TO APPROVE THE COMPANY'S 2017 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RATIFY THE SELECTION OF BDO USA LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**SAGE THERAPEUTICS, INC.**

<b>Security</b>	78667J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SAGE	<b>Meeting Date</b>	07-Jun-2017
<b>Record Date</b>	10-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1A.	ELECTION OF DIRECTOR: MICHAEL COLA	Management	For	For
1B.	ELECTION OF DIRECTOR: JEFFREY M. JONAS	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS.	Management	For	For

## SAREPTA THERAPEUTICS INC.

<b>Security</b>	803607100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SRPT	<b>Meeting Date</b>	06-Jun-2017
<b>Record Date</b>	11-Apr-2017		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1.1	ELECTION OF GROUP II DIRECTOR: RICHARD J. BARRY	Management	For	For
1.2	ELECTION OF GROUP II DIRECTOR: M. KATHLEEN BEHRENS, PH.D.	Management	For	For
1.3	ELECTION OF GROUP II DIRECTOR: CLAUDE NICAISE, M.D.	Management	For	For
2.	ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	ADVISORY VOTE ON WHETHER AN ADVISORY VOTE ON EXECUTIVE COMPENSATION SHOULD BE HELD EVERY ONE, TWO OR THREE YEARS	Management	1 Year	For
4.	RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017	Management	For	For

---

## SHIRE PLC

<b>Security</b>	82481R106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SHPG	<b>Meeting Date</b>	25-Apr-2017
<b>Record Date</b>	23-Mar-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	TO RECEIVE THE COMPANY S ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2016.	Management	For	For
2.	TO APPROVE THE DIRECTORS REMUNERATION REPORT, EXCLUDING THE DIRECTORS REMUNERATION POLICY, SET OUT ON PAGES 82 TO 114 OF THE ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2016.	Management	For	For
3.	TO RE-ELECT DOMINIC BLAKEMORE AS A DIRECTOR.	Management	For	For
4.	TO RE-ELECT OLIVIER BOHUON AS A DIRECTOR.	Management	For	For
5.	TO RE-ELECT WILLIAM BURNS AS A DIRECTOR.	Management	For	For
6.	TO ELECT IAN CLARK AS A DIRECTOR.	Management	For	For
7.	TO ELECT GAIL FOSLER AS A DIRECTOR.	Management	For	For
8.	TO RE-ELECT DR. STEVEN GILLIS AS A DIRECTOR.	Management	For	For
9.	TO RE-ELECT DR. DAVID GINSBURG AS A DIRECTOR.	Management	For	For
10.	TO RE-ELECT SUSAN KILSBY AS A DIRECTOR.	Management	For	For
11.	TO RE-ELECT SARA MATHEW AS A DIRECTOR.	Management	For	For
12.	TO RE-ELECT ANNE MINTO AS A DIRECTOR.	Management	For	For
13.	TO RE-ELECT DR. FLEMMING ORNSKOV AS A DIRECTOR.	Management	For	For
14.	TO RE-ELECT JEFFREY POULTON AS A DIRECTOR.	Management	For	For
15.	TO ELECT ALBERT STROUCKEN AS A DIRECTOR.	Management	For	For
16.	TO RE-APPOINT DELOITTE LLP AS THE COMPANY S AUDITOR UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING OF THE COMPANY.	Management	For	For
17.	TO AUTHORIZE THE AUDIT, COMPLIANCE & RISK COMMITTEE TO DETERMINE THE REMUNERATION OF THE AUDITOR.	Management	For	For
18.	THAT THE AUTHORITY TO ALLOT RELEVANT SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES )) CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (B) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE AUTHORISED ALLOTMENT AMOUNT SHALL BE: (A) 15,104,181.75 OF RELEVANT SECURITIES AND (B) SOLELY IN CONNECTION WITH AN ALLOTMENT PURSUANT TO AN OFFER BY WAY OF A RIGHTS ISSUE (AS DEFINED IN THE ARTICLES, BUT ONLY IF AND TO THE EXTENT THAT SUCH OFFER IS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
19.	THAT, SUBJECT TO THE PASSING OF RESOLUTION 18, THE AUTHORITY TO ALLOT EQUITY	Management	For	For

	SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES )) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (D) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE NON PRE-EMPTIVE AMOUNT (AS DEFINED IN THE ARTICLES) SHALL BE 2,265,627.25 AND THE ALLOTMENT PERIOD SHALL BE THE PERIOD COMMENCING ON APRIL 25, 2017, AND ENDING ON THE EARLIER OF THE CLOSE OF ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)			
20.	THAT, SUBJECT TO THE PASSING OF RESOLUTIONS 18 AND 19 AND FOR THE PURPOSE OF THE AUTHORITY TO ALLOT EQUITY SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES )) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (D) OF THE ARTICLES AND RENEWED BY RESOLUTION 19, THE NON PRE-EMPTIVE AMOUNT (AS DEFINED IN THE ARTICLES) SHALL BE INCREASED FROM 2,265,627.25 TO 4,531,254.50 AND THE ALLOTMENT PERIOD SHALL BE THE PERIOD COMMENCING ON ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
21.	THAT THE COMPANY BE AND IS HEREBY GENERALLY AND UNCONDITIONALLY AUTHORIZED: (A) PURSUANT TO ARTICLE 57 OF THE COMPANIES (JERSEY) LAW 1991 TO MAKE MARKET PURCHASES OF ORDINARY SHARES IN THE CAPITAL OF THE COMPANY, PROVIDED THAT: (1) THE MAXIMUM NUMBER OF ORDINARY SHARES HEREBY AUTHORIZED TO BE PURCHASED IS 90,625,090, (2) THE MINIMUM PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID FOR AN ORDINARY SHARE IS FIVE PENCE, (3) THE MAXIMUM PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
22.	THAT, WITH EFFECT FROM THE CONCLUSION OF THE ANNUAL GENERAL MEETING, THE COMPANY S ARTICLES OF ASSOCIATION BE AMENDED AND THOSE ARTICLES PRODUCED TO THE MEETING AND INITIALED BY THE CHAIRMAN BE ADOPTED AS THE COMPANY S ARTICLES OF ASSOCIATION, IN SUBSTITUTION FOR, AND TO THE EXCLUSION OF, THE EXISTING ARTICLES OF ASSOCIATION OF THE COMPANY.	Management	For	For
23.	TO APPROVE THAT A GENERAL MEETING OF THE COMPANY, OTHER THAN AN ANNUAL GENERAL MEETING, MAY BE CALLED ON NOT LESS THAN 14 CLEAR DAYS NOTICE.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**SPARK THERAPEUTICS, INC.**

<b>Security</b>	84652J103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ONCE	<b>Meeting Date</b>	31-May-2017
<b>Record Date</b>	11-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 STEVEN M. ALTSCHULER MD		For	For
	2 LARS G. EKMAN, M.D. PHD		For	For
	3 KATHERINE A. HIGH, M.D.		For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RECOMMEND, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	1 Year	For
4.	TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**TETRAPHASE PHARMACEUTICALS, INC.**

<b>Security</b>	88165N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TTPH	<b>Meeting Date</b>	31-May-2017
<b>Record Date</b>	05-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 L PATRICK GAGE		For	For
	2 NANCY WYSENSKI		For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For

**ULTRAGENYX PHARMACEUTICAL INC.**

<b>Security</b>	90400D108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARE	<b>Meeting Date</b>	22-Jun-2017
<b>Record Date</b>	24-Apr-2017		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Mgmt</b>
1A.	ELECTION OF DIRECTOR: EMIL D. KAKKIS, M.D., PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: DANIEL G. WELCH	Management	For	For
2.	RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	For	For

---



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

VENITI, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Aug-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	SERIES D PREFERRED STOCK FINANCING	Management	For	For
2.	AUTHORIZATION OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
3.	WAIVER OF PREEMPTIVE RIGHTS AND NOTICE	Management	For	For
4.	ADOPTION OF THE MERGER DOCUMENTS	Management	For	For
5.	ADOPTION OF FORMS OF STOCK OPTION AGREEMENT	Management	For	For
6.	WAIVER OF APPRAISAL AND DISSENTERS RIGHTS	Management	For	For
7.	WAIVER OF NOTICE	Management	For	For
8.	TERMINATION OF CERTAIN AGREEMENTS	Management	For	For
9.	APPOINTMENT OF STOCKHODLER REPRESENTATIVE COMMITTEE	Management	For	For
10.	OMNIBUS RESOLUTIONS	Management	For	For

VENITI, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	25-Apr-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	INCREASE IN 2010 EQUITY INCENTIVE PLAN	Management	For	For

VERONA PHARMA PLC

<b>Security</b>	GB00B6GSH43	<b>Meeting Type</b>	Annual General Meeting
<b>Ticker Symbol</b>	VRNA	<b>Meeting Date</b>	12-Apr-2017
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1	TO RECEIVE AND ADOPT THE REPORT OF THE DIRECTORS AND THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2016	Management	For	For
2	TO RE-ELECT SVEN JAN-ANDERS KARISSON AS A DIRECTOR OF THE COMPANY	Management	For	For
3	TO RE-ELECT RISHI GUPTA AS A DIRECTOR OF THE COMPANY	Management	For	For
4		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	TO RE-ELECT MAHENDRA SHAH AS A DIRECTOR OF THE COMPANY			
5	TO RE-ELECT ANDREW SINCLAIR AS A DIRECTOR OF THE COMPANY	Management	For	For
6	TO RE-ELECT VIKAS SINHA AS A DIRECTOR OF THE COMPANY	Management	For	For
7	TO APPOINT PRICEWATERHOUSECOOPERS LLP AS AUDITORS	Management	For	For
8	TO APPROVE THE COMPANY S NEW INCENTIVE PLAN	Management	For	For
9	TO APPROVE AND RATIFY THE COMPANY S OLD INCENTIVE PLANS	Management	For	For
10	TO AUTHORIZE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006	Management	For	For
11	TO AUTHORIZE THE DIRECTORS TO ALLOT EQUITY SECURITIES PURSUANT TO SECTION 570 OF THE COMPANIES ACT 2006	Management	For	For

VERONA PHARMA PLC, CARDIFF

<b>Security Ticker Symbol Record Date</b>	GB00B6GSH43 VRNA N/A	<b>Meeting Type Meeting Date</b>	Ordinary General Meeting 08-Feb-2017
---	----------------------------	----------------------------------	---

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1	TO APPROVE THE PROPOSED CONSOLIDATION OF EVERY 50 ORDINARY SHARES OF GBP 0.001 EACH INTO ONE ORDINARY SHARE OF GBP 0.05 EACH AS SET OUT IN THE NOTICE OF THE GENERAL MEETING DATED 18TH JANUARY 2017	Management	For	For
2	TO AUTHORISE THE DIRECTORS TO ALLOT SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR, OR TO CONVERT ANY SECURITY INTO, SHARES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006 IN RELATION TO THE POTENTIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND THE POTENTIAL CONCURRENT PRIVATE PLACEMENT AS SET OUT IN THE NOTICE OF THE GENERAL MEETING DATED 18TH JANUARY 2017	Management	For	For
3	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES PURSUANT TO SECTION 570 OF THE COMPANIES ACT 2006 RESTRICTED TO THE ALLOTMENT OF THE ORDINARY SHARES AUTHORISED FOR ALLOTMENT IN RESOLUTION 2 AS SET OUT IN THE NOTICE OF THE GENERAL MEETING DATED 18TH JANUARY 2017	Management	For	For
4	TO ADOPT THE NEW ARTICLES OF ASSOCIATION OF THE COMPANY IN SUBSTITUTION FOR AND TO THE ENTIRE EXCLUSION OF THE EXISTING ARTICLES OF ASSOCIATION	Management	For	For

## VERTEX PHARMACEUTICALS INCORPORATED

<b>Security</b>	92532F100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	VRTX	<b>Meeting Date</b>	08-Jun-2017
<b>Record Date</b>	12-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 ALAN GARBER		For	For
	2 MARGARET G. MCGLYNN		For	For
	3 WILLIAM D. YOUNG		For	For
2.	AMENDMENTS TO OUR CHARTER AND BY-LAWS TO PROVIDE FOR THE DECLASSIFICATION OF OUR BOARD OF DIRECTORS.	Management	For	For
3.	AMENDMENT AND RESTATEMENT OF OUR 2013 STOCK AND OPTION PLAN, TO AMONG OTHER THINGS, INCREASE THE NUMBER OF SHARES AVAILABLE UNDER THE PLAN BY 6.75 MILLION SHARES.	Management	For	For
4.	RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017.	Management	For	For
5.	ADVISORY VOTE ON OUR NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
6.	ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION PROGRAM.	Management	1 Year	For
7.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE TAKE STEPS NECESSARY TO ELIMINATE SUPERMAJORITY PROVISIONS FROM OUR CHARTER AND BY-LAWS.	Shareholder	Against	For
8.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE PREPARE A REPORT ON OUR POLICIES AND ACTIVITIES WITH RESPECT TO LOBBYING.	Shareholder	Against	For

## XENCOR INC

<b>Security</b>	98401F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XNCR	<b>Meeting Date</b>	22-Jun-2017
<b>Record Date</b>	27-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1 DR. BASSIL I. DAHIYAT		For	For
	2 DR. KEVIN C. GORMAN		For	For
	3 DR. A. BRUCE MONTGOMERY		For	For
	4 KURT GUSTAFSON		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

5	YUJIRO S. HATA		For	For
2.	PROPOSAL TO RATIFY RSM US LLP AS THE INDEPENDENT PUBLIC ACCOUNTING FIRM FOR 2017.	Management	For	For
3.	PROPOSAL TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY MATERIALS.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For

---

## XENON PHARMACEUTICALS INC

<b>Security</b>	98420N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XENE	<b>Meeting Date</b>	01-Jun-2017
<b>Record Date</b>	04-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	MICHAEL TARNOW	For	For
	2	MOHAMMAD AZAB	For	For
	3	STEVEN GANNON	For	For
	4	MICHAEL HAYDEN	For	For
	5	FRANK HOLLER	For	For
	6	GARY PATOU	For	For
	7	SIMON PIMSTONE	For	For
	8	RICHARD SCHELLER	For	For
	9	DAWN SVORONOS	For	For
2.	APPOINTMENT OF KPMG LLP AS AUDITORS	Management	For	For
3.	AUTHORIZING THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF THE CORPORATION TO FIX THE REMUNERATION TO BE PAID TO THE AUDITOR	Management	For	For

## ZAFGEN, INC.

<b>Security</b>	98885E103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ZFGN	<b>Meeting Date</b>	21-Jun-2017
<b>Record Date</b>	24-Apr-2017		

Item	Proposal	Proposed by	Vote	For/Against Mgmt
1.	DIRECTOR	Management		
	1	THOMAS E. HUGHES, PH.D.	For	For
	2	JOHN L. LAMATTINA, PH.D	For	For
	3	FRANK E. THOMAS	For	For
2.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For

**SIGNATURES**

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)                      Tekla Life Sciences Investors

By (Signature and Title)\*

/s/ Daniel R. Omstead  
(Daniel R. Omstead, President)

Date                                      8/30/17

---

\*Print the name and title of each signing officer under his or her signature.